Seminars in Nuclear Medicine
Volume 37, Issue 6 , Pages 400-419 , November 2007

18F-Labeled Positron Emission Tomographic Radiopharmaceuticals in Oncology: An Overview of Radiochemistry and Mechanisms of Tumor Localization

  • Shankar Vallabhajosula, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Shankar Vallabhajosula, PhD, Professor of Radiochemistry and Radiopharmacy in Radiology, Citigroup Biomedical Imaging Center (CBIC), Weill Cornell Medical College, Cornell University, 516 East 72nd Street, New York, NY 10021.

References 

  1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70
  2. Warburg O, Posener K, Negelein E. The metabolism of cancer cells. Biochem Zeitschr. 1924;152:129–169
  3. Warburg O. On the origin of cancer cells. Science. 1956;123:309–314
  4. Smith TA. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci. 2000;57:170–178
  5. Laszlo J, Humphreys SR, Goldin A. Effects of glucose analogues (2-deoxy-D-glucose, 2-deoxy-D-galactose) on experimental tumors. J Natl Cancer Inst. 1960;24:267–281
  6. Pacák J, Cerny M. History of the First Synthesis of 2-Deoxy-2-Fluoro-D-Glucose the Unlabeled Forerunner of 2-Deoxy-2-[18F]Fluoro-D-Glucose. Mol Imaging Biol. 2002;4:353–354
  7. Ido T, Wan CN, Casella JS, et al. Labeled 2-deoxy-D-glucose analogs: 18F labeled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose and 14C-2-deoxy-2-fluoro-D-glucose. J Label Compd Radiopharmacol. 1978;14:175–183
  8. Nutt R. The history of positron emission tomography (PET). Mol Imag Biol. 2002;4:11–26
  9. Department of Health And Human Services. Food and Drug Administration [Docket No. 00N–0553] Positron Emission Tomography Drug Products; Safety and Effectiveness of Certain PET Drugs for Specific Indications. Federal Register. 2000;65(48):12999–13010
  10. Wahl RL. Principles of cancer imaging with fluorodeoxyglucose. In:  Wahl RL,  Buchanan JW editor. Principles and Practice of Positron Emission Tomography. Lippincott: Williams & Wilkins; 2002;
  11. Rajendran JG, Mankoff DA. Beyond Detection: Novel applications for PET Imaging to guide cancer therapy. J Nucl Med. 2007;48:855–856
  12. Stocklin GL. Is there a future for clinical fluorine-18 radiopharmaceuticals (excluding FDG)?. Eur J Nucl Med. 1998;25:1612–1616
  13. Varagnolo L, Stokkel MPM, Mazzi U, et al. 18F-labeled radiopharmaceuticals for PET in oncology, excluding FDG. Nuc Med Biol. 2000;27:103–112
  14. Shiue CY, Welch MJ. Update on PET radiopharmaceuticals: Life beyond fluorodeoxyglucose. Radiol Clin N Am. 2004;42:1033–1053
  15. Couturier O, Luxen A, Chatal1 JF, et al. Fluorinated tracers for imaging cancer with positron emission tomography. Eur J Nucl Med Mol Imag. 2004;31:1182–1206
  16. Vallabhajosula S. Radiopharmaceuticals for PET, in Biersack HJ, Freeman L (eds.) Practical Nuclear Medicine, in press
  17. Sols A, Crane RA. Substrate specificity of brain hexokinase. J Biol Chem. 1954;210:581–595
  18. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med. 2005;46:1356–1367
  19. Hamaoka T, Madewell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942–2953
  20. Volker JF, et al. The absorption of fluorides by enamel, dentin, bone, and hydroxyapatite as shown by the radioactive isotope. J Biol Chem. 1940;134:543–548
  21. Blau M, Nagler W, Bender MA. A new isotope for bone scanning. J Nucl Med. 1962;3:332–334
  22. Blake GM, Park-Holohan SJ, Cook GJ, et al. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med. 2001;31:28–49
  23. Schiepers C, Nuytes J, Bormans G, et al. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med. 1997;38:1970–1976
  24. Even-Sapir E, Metser U, Flusser G, et al. Assessment of malignant skeletal disease with 18F-fluoride PET/CT. J Nucl Med. 2004;45:272–278
  25. Cleaver JE. Thymidine metabolism and cell kinetics. Front Biol. 1967;6:43–100
  26. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem. 1988;263:8350–8358
  27. Livingston RB, Ambus U, George SL, et al. In vitro determination of thymidine-[H-3] labeling index in human solid tumors. Cancer Res. 1974;34:1376–1380
  28. Christman D, Crawford EJ, Friedkin M, et al. Detection of DNA synthesis in intact organisms with positron-emitting methyl-[C-11]-thymidine. Proc Natl Acad Sci USA. 1972;69:988–992
  29. Ishiwata K, Ido T, Abe Y, et al. Studies on 18F-labeled pyrimidines III (Biochemical investigation of 18F-labeled pyrimidines and comparison with 3H-deoxythymidine in tumor-bearing rats and mice). Eur J Nucl Med. 1985;10:39–44
  30. Shields AF, Grierson JR, Kozawa SM, et al. Development of labeled thymidine analogs for imaging tumor proliferation. Nucl Med Biol. 1996;23:17–22
  31. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334–1336
  32. Seitz U, Wagner M, Neumaier B, et al. Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3′-[18F]fluoro-3′-deoxythymidine ([18F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging. 2002;29:1174–1181
  33. Grierson JR, Schwartz JL, Muzi M, et al. Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: Validations for positron emission tomography. Nucl Med Biol. 2004;31:829–837
  34. Crawford EJ, Friedkin M, Wolf AP, et al. 18F-5-Fluorouridine, a new probe for measuring the proliferation of tissue in vivo. Adv Enz Regul. 1982;20:3–22
  35. Shields AF. PET imaging with 18F-FLT and thymidine analogs: Promise and pitfalls. J Nucl Med. 2003;44:1432–1434
  36. Zeisel SH. Dietary choline: Biochemistry, physiology, and pharmacology. Annu Rev Nutr. 1981;1:95–121
  37. Institute of Medicine: Food and Nutrition Board. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantotheni Acid, Biotin and Choline. Washington, DC: National Academy Press; 1998;
  38. Clary GL, Tsai C-F, Guynn RW, et al. Substrate specificity of choline kinase. Arch Biochem Biophys. 1987;254:214–221
  39. Wettstein M, Weik C, Holneicher C, et al. Betaine as an osmolyte in rat liver: metabolism and cell-to-cell interactions. Hepatology. 1998;27:787–793
  40. Roivainen A, Forsback S, Grönroos T, et al. Blood metabolism of [methyl-11C]choline; implications for in vivo imaging with positron emission tomography. Eur J Nucl Med. 2000;27:25–32
  41. Jackowski S. Coordination of membrane phospholipid synthesis with the cell cycle. J Biol Chem. 1994;269:3858–3867
  42. Cornell R, Grove GL, Rothblat GH, et al. Lipid requirement for cell cycling: The effect of selective inhibition of lipid synthesis. Exp Cell Res. 1997;109:299–307
  43. Tedeschi G, Lundbom N, Raman R, et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: A serial proton magnetic resonance spectroscopy imaging study. J Neurosurg. 1997;87:516–524
  44. Hara T, Kosaka N, Shinoura N, et al. PET imaging of brain tumor with [methyl-11C] choline. J Nucl Med. 1997;38:842–847
  45. Hara T, Kosaka N, Kishi H. Development of [18F]-Fluoroethylcholine for cancer imaging with PET: Synthesis, biochemistry, and prostate cancer imaging. J Nucl Med. 2002;43:187–199
  46. DeGrado TR, Coleman RE, Wang S, et al. Synthesis and evaluation of 18F labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer. Cancer Res. 2001;61:110–117
  47. Henriksen G, Herz M, Hauser A, et al. Synthesis and preclinical evaluation of the choline transport tracer deshydroxy-[18F]fluorocholine ([18F]dOC). Nucl Med Biol. 2004;31:851–858
  48. Howard BV, Howard WJ. Lipids in normal and tumor cells in culture. Prog Biochem Pharmacol. 1975;10:135–166
  49. Swinnen JV, Van Veldhoven PP, Timmermans L, et al. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun. 2003;302:898–903
  50. Oyama N, Miller TR, Dehdashti F, et al. 11C-acetate PET imaging of prostate cancer: Detection of recurrent disease at PSA relapse. J Nucl Med. 2003;44:549–555
  51. Ponde DE, Oyama N, Dence CS, et al. [18F]-Fluoroacetate, an analogue of C-11 acetate for tumor imaging. J Nucl Med. 2003;44:296p
  52. Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 2004;34:274–292
  53. Yoshimoto M, Waki A, Obata A, et al. Radiolabeled choline as a proliferation marker: Comparison with radiolabeled acetate. Nuclear Medicine andNucl Med Biol. 2004;31:859–865
  54. Jager PL, Vaalburg W, Pruim J, et al. Radiolabeled amino acids: Basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432–445
  55. Langen KJ, Jarosch M, Muhlensiepen H, et al. Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nucl Med Biol. 2003;30:501–508
  56. Saier MH, Daniels GA, Boerner P, et al. Neutral amino acid transport systems in animal cells: Potential targets of oncogene action and regulators of cellular growth. J Membr Biol. 1988;104:1–20
  57. Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature. 1983;305:137–138
  58. Luxen A, Perlmutter M, Bida GT, et al. Remote, semiautomated production of 6-[18F]fluoro-L-dopa for human studies with PET. Int J Rad Appl Instrum A. 1990;41:275–281
  59. Luxen A, Guillaume M, Melega WP, et al. Production of 6-[18F]fluoro-L-dopa and its metabolism in vivo—a critical review. Int J Rad Appl Instrum B. 1992;19:149–158
  60. Hoegerle S, Altehoefer C, Ghanem N, et al. 18F-DOPA positron emission tomography for tumor detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001;28:64–71
  61. Hoegerle S, Nitzsche E, Altehoefer C, et al. Pheochromocytomas: Detection with 18F DOPA whole body PET—initial results. Radiology. 2002;222:507–512
  62. Becherer A, Szabo M, Karanikas G, et al. Imaging of advanced neuroendocrine tumors with [18]F-FDOPA PET. J Nucl Med. 2004;45:1161–1167
  63. Gazdar AF, Helman LJ, Israel MA, et al. Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res. 1988;48:4078–4082
  64. Inoue TJ, Tomiyoshi K, Higuchi T, et al. : Biodistribution studies on L-3-[18F]fluoro-α-methyl tyrosine: A potential tumor-detecting agent. J Nucl Med. 1998;39:663–667
  65. Shoup TM, Olson JMH, Votaw J, et al. Synthesis and evaluation of [18F] 1-amino-3-fluorocyclobutane-l-carboxylic acid to image brain tumors. J Nucl Med. 1999;40:331–338
  66. Vaupel P, Schlenger K, Hoeckel M. Blood flow and tissue oxygenation of human tumors: An update. Adv Exp Med Biol. 1992;317:139–151
  67. Foo SS, Abbott DF, Lawrentschuk N, et al. Functional imaging of intra-tumoral hypoxia. Mol Imaging Biol. 2004;6:291–305
  68. Chapman JD, Franko AJ, Sharplin J. A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer. 1981;43:546–550
  69. Whitmore GF, Varghese AJ. The biological properties of reduced nitroheterocyclics and possible underlying biochemical mechanisms. Biochem. Pharmacol. 1986;35:97–103
  70. Rasey JS, Grunbaum Z, Magee S, et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res. 1987;111:292–304
  71. Rajendran JG, Schwartz DL, O’Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435–5441
  72. Gronroos T, Eskola O, Lehtio K, et al. Pharmacokinetics of [18F]FETNIM: A potential marker for PET. J Nucl Med. 2001;42:1397–1404
  73. Rasey JS, Hofstrand PD, Chin LK, et al. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med. 1999;40:1072–1079
  74. Piert M, Machulla HJ, Picchio M, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med. 2005;46:106–113
  75. Beck R, Roper B, Carlsen JM, et al. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med. 2007;48:973–980
  76. Van de Wiele C, De Vos F, Slegers G, et al. Radiolabeled estradiol derivatives to predict response to hormonal treatment in breast cancer: Areview. Eur J Nucl Med. 2000;27:1421–1433
  77. Mosselman S, Pohlman J, Dijkema R. ERβ identification and characterisation of a novel human estrogen receptor. FEBS Lett. 1996;392:49–53
  78. Vollenweider-Zerargui L, Barrelet L, Wong Y, et al. The predictive value of estrogen and progesterone receptors’ concentrations on the clinical behavior of breast cancer in women: Clinical correlation on 547 patients. Cancer. 1986;57:1171–1180
  79. Jensen EV, DeSombre ER, Jungblut PW. Estrogen receptors in hormone-responsive tissue and tumors. In:  Wissler RW,  Dao TL,  Wood S editor. Endogenous factors influencing host tumor balance. Chicago: University of Chicago Press; 1967;
  80. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin N Am. 2005;43:153–167
  81. Kiesewetter DO, Kilbourn MR, Landvatter SW, et al. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med. 1984;25:1212–1221
  82. Mankoff DA, Tewson TJ, Eary JF. Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16α-fluoroestradiol (FES). Nucl Med Biol. 1997;24:341–348
  83. Ahmed N, Langlois R, Rodrigue S, et al. Automated synthesis of 11β-methoxy-4-16α-[16α-18F]difluoroestradiol (4F-M[18F]FES) for estrogen receptor imaging by positron emission tomography. Nucl Med Biol. 2007;34:459–464
  84. Seimbille Y, Ali H, van Lier JE. Synthesis of 2, 16α- and 4,16α difluoroestradiols and their 11β-methoxy derivatives as potential estrogen receptor-binding radiopharmaceuticals. J Chem Soc Perkin Trans. 2002;1:657–663
  85. Ruth TJ, Wolf AP. Absolute cross section for the production of 18F via the 18O(p,n)18F reaction. Radiochimica Acta. 1979;26:21–24
  86. Schlyer DJ. Production of radionuclides in accelerators. In:  Welch MJ,  Redvanley CS editor. Handbook of Radiopharmaceuticals, Radiochemistry and Applications. New York: John Wiley & Sons Inc; 2003;
  87. Nickels RJ, Hichwa RD, Daube ME, et al. An 18O target for the high yield production of 18F fluoride. Int J Appl Rad Isotop. 1983;34:625–629
  88. Nickels RJ, Daube ME, Ruth TJ. An oxygen target for the production of [18F]F2. Appl Radiat Isot. 1984;35:117-112
  89. Kilbourn MR. Fluorine-I8 labeling of radiopharmaceuticals (Nuclear Science Series no. NAS-NS-3203). Washington, DC: National Academy of Sciences, National Academy Press; 1990;
  90. Block D, Coenen HH, Stocklin G, et al. The NCA nucleophilic 18F-fluorination of I,N-disubstituted alkanes as fluoralkylation agents. J Label Compd Radiopharm. 1987;24:1029–1042
  91. Firnau G, Nahmias C, Garnett ES. The preparation of [18F]5-fluoro-DOPA with reactor produced fluorine-18. Int J Appl Radiat Isot. 1973;24:182–184
  92. Firnau G, Chiakal R, Garnett ES. Aromatic radiofluorination with 18F fluorine gas: 6-[18F]fluoro-L-dopa. J Nucl Med. 1984;25:1228–1233
  93. Adam MJ, Ruth TJ, Grierson JR, et al. Routine synthesis of L-[18F]6-fluorodopa with fluorine-18 acetyl hypofluorite. J Nucl Med. 1986;27:1462–1466
  94. Namavari M, Bishop A, Satyamurthy N, et al. Regioselective radiofluorodestannylation with [18F]F2 and [18F]CH3COOF (A high yield synthesis of 6-[18F]Fluoro-L-DOPA). Int J Rad Appl Instrum. 1992;43:989–996
  95. Dolle F, Demphel S, Hinnen F, et al. 6-[18F]Fluoro-L- DOPA by Radiofluoro-destannylation: A short and simple synthesis of a new labeling precursor. J Label Compd Radiopharm. 1998;41:105–114
  96. Wilson I, Chatterjee S, Wolf W. The use of 3′-fluoro-3′-deoxythymidine and studies of its 18F-radiolabeling, as a tracer for the non-invasive monitoring of the biodistribution of drugs against AIDS. J Fluorine Chem. 1991;55:283–289
  97. Grierson JR, Shields AF. An improved radiosynthesis of [F-18]FLT. J Labelled Compd Radiopharm. 1999;42:S525–S526
  98. Grierson JR, Shields AF. Radiosynthesis of 3′-Deoxy-3′-[18F]fluoro thymidine:[18F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol. 2000;27:143–156
  99. Martin SJ, Eisenbarth U, Wagner-Utermann U, et al. A new precursor for the radiosynthesis of [18F]FLT. Nucl Med Biol. 2002;29:263–273
  100. Yun M, Oh SJ, Ha H-J, et al. High radiochemical yield synthesis of 3′-deoxy-3′-[18F]Fluorothymidine using (5′-O-dimethoxytirtyl-2′-deoxy-3′-Onosyl-D-threo-pentofuranosyl)thymine and its 3-N-BOC protected analogue as a labeling precursor. Nucl Med Biol. 2003;30:151–157
  101. Suehiro M, Vallabhajosula S, Goldsmith SJ, et al: Investigation of the role of the base in the synthesis of [18F]FLT. Applied Radiat Isotop 2007 (in Press)
  102. Oh SJ, Mosdzianowski C, Chi DY, et al. Fully automated synthesis system of 3′-deoxy-3′-[18F]fluorothymidine. Nucl Med Biol. 2004;31:803–809
  103. Jerabeck PA, Patrick TB, Kilbourn MR, et al. Synthesis and biodistribution of 18F labeled fluoronitroimidazoles: Potential in vivo markers of hypoxic tissue. Int J Radiat Appl Instrum. 1986;37:599–605
  104. Grierson JR, Link JM, Mathis CA, et al. A radiosynthesis of fluorine-18 fluoromisonidazole. J Nucl Med. 1989;30:343–350
  105. Lim JL, Berridge MS. An efficient radiosynthesis of [18F]fluoromisonidazole. Appl Radiat Isot. 1993;44:1085–1091
  106. Cherif A, Yang DJ, Tansey W, et al. Rapid synthesis of 3-[18F]fluoro-1-(2′-nitro-1′-imidazolyl)-2-propanol [18F]fluoromisonidazole). Pharm Res. 1994;11:466–469
  107. Patt M, Kuntzsch M, Machulla HJ. Preparation of [18F]fluoromisonidazole by nucleophilic substitution on THP-protected precursor: Yield dependence on reaction parameters. J Radioanal Nucl Chem. 1999;240:925–927
  108. Kamarainen EL, Kyllonen T, Nihtila O, et al. Preparation of fluorine-18-labelled fluoromisonidazole using different synthesis methods. J Label Compd Radiopharm. 2004;47:37–45
  109. Tang G, Wang M, Tang X, Gan M, Luo L. Fully automated one-pot synthesis of [18F]fluoromisonidazole. Nucl Med Biol. 2005;32:553–558
  110. Kiesewetter DO, Kilbourn MR, Landvatter SW, et al. Preparation of four fluorine-18 labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med. 1984;25:1212–1221
  111. Tewson TJ. Synthesis of 16α-fluoroestradiol using fluoride ion as a source of fluorine. J Nucl Med. 1983;24:P52
  112. Lim JL, Zheng L, Berridge MS, et al. The use of 3-methoxymethyl-l6β, 17β-epiestriol-O-cyclic sulfone as the precursor in the synthesis of F-l 8-16α-fluoroestradiol. Nucl Med Biol. 1996;23:911–915
  113. Romer J, Fuchtner F, Steinbach J, et al. Automated production of 16α-[18F]fluoroestradiol for breast cancer imaging. Nucl Med Biol. 1999;26:473–479
  114. Hara T, Yuasa M, Yoshida H. Automated synthesis of fluorine-18 labeled choline analogue: 2-fluoroethyl-dimethyl-2-oxyethylammonium. [abstract] J Nucl Med. 1997;38:44P
  115. DeGrado TR, Coleman RE, Wang S, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer. Cancer Res. 2001;61:110–117
  116. DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of [18]F-labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001;42:1805–1814
  117. Tadino V, Kothari PJ, Vallabhajosula S, et al. [18F]-Fluoroalkylation using the “Loop” System. J Nucl Med. 2004;45:P445
  118. Vallabhajosula S, Kostakoglu L, Kothari PJ, et al. Pharmacokinetics and Biodistribution of Radiolabelled Choline in human Subjects: Comaprison of [11C]Choline and [18F]Fluorocholine. J Label Compd Radiopharm. 2005;48:S281
  119. Iwata R, Pascali C, Bogni A, et al. [18F]Fluoromethyl triflate, a novel and reactive [18F]fluoromethylating agent: Preparation and application to the on-column preparation of [18F]fluorocholine. Appl Radiat Isot. 2002;57:347–352
  120. Jones SC, Alavi A, Christman D, et al. The radiation dosimetry of 2-[F-18]fluoro-2-deoxy-D-glucose in man. J Nucl Med. 1982;23:613–617
  121. Hays MT, Watson EE, Thomas SR, et al. MIRD Dose Estimate Report No. 19: Radiation Absorbed Dose Estimates from 18F-FDG J Nucl Med. 2002;43:210–214
  122. Brix G, Lechel U, Glatting G, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med. 2005;46:608–613
  123. ICRP Publication 53: [18F]Fluoride radiation dosimetry. Volume. 1987;18:73–74
  124. Mejia AA, Nakamura T, Itoh M, et al. Absorbed dose estimates in positron emission tomography studies based on the administration of 18Flabeled radiopharmaceuticals. J Radiat Res. 1991;32:243–261
  125. Harvey J, Firnau G, Garnett ES. Estimation of the radiation dose in man due to 6-[18F]fluoro-L-dopa. J Nucl Med. 1985;26:931–935
  126. Vesselle H, Grierson J, Peterson LM, et al. 18F-fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med. 2003;44:1482–1488
  127. Tolvanen T, Lehtio K, Kulmala J, et al. 18F-Fluoroerythronitroimidazole radiation dosimetry in cancer studies. J Nucl Med. 2002;43:1674–1680
  128. Mankoff DA, Peterson LM, Tewson TJ, et al. [18F]fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med. 2001;42:679–684
  129. DeGrado TR, Reiman RE, Price DT, et al. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med. 2002;43:92–96
  130. Department of Health And Human Services. Food and Drug Administration [Docket Nos. 94D–0422 and 93N–0005] Revocation of Certain Guidance Documents on Positron Emission Tomography Drug Products. Federal Register. 1997;62(244):66636
  131. Department of Health And Human Services. Food and Drug Administration [Docket No. 1998D-0266] Draft Guidance on Current Good Manufacturing Practice for Positron Emission Tomography Drug Products. Federal Register. 2005;70(181):55038-55062 and 55145

PII: S0001-2998(07)00090-6

doi: 10.1053/j.semnuclmed.2007.08.004

Seminars in Nuclear Medicine
Volume 37, Issue 6 , Pages 400-419 , November 2007

Article Tools

* Image Usage & Resolution